Novartis Korea Ltd.
🇰🇷South Korea
Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
Phase 3
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- Novartis Korea Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT00967213
- Locations
- 🇰🇷
Dept. of Ophthalmology, KyungHee Medical Center, #1 Hoegi, Dongdaemun-gu, Seoul, Korea, Republic of
Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)
Phase 3
Completed
- Conditions
- Macular EdemaRetinal Vein Occlusion
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Novartis Korea Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT00942864
- Locations
- 🇰🇷
Dept. of ophthalmology, Kyung Hee University Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath